[Federal Register Volume 59, Number 247 (Tuesday, December 27, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-31768]


[[Page Unknown]]

[Federal Register: December 27, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Exclusive License: Macrophage Stimulating 
Protein

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a limited field of use exclusive license in the United States to 
practice the invention embodied in U.S. Patent Number 5,219,991, filed 
on September 21, 1990, and issued on June 15, 1993, entitled 
``Macrophage Stimulating Protein'', to Toyobo Co., Ltd., having a place 
of business in Cambridge, Massachusetts. The patent rights in this 
invention have been assigned to the United States of America.
    The patent claims macrophage stimulating protein (MSP) and further 
relates to antibodies to MSP. It also claims a method of purifying MSP.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use would be limited to the use of MSP as an anti-
fungal agent, in opportunistic infections in immunocompromised 
individuals and against viral or mycobacterial infections.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Leopold J. Luberecki, Jr., J.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 
20852-3804. Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-
0220. Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Only written comments and/or application for a 
license which are received by the NIH Office of Technology Transfer on 
or before February 27, 1995, will be considered.

    Dated: December 16, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-31768 Filed 12-23-94; 8:45 am]
BILLING CODE 4140-01-P